Ken Uchibori

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 17

Top Venues

Thoracic cancer

NPJ precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer (2024)
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer 15 (5) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer 15 (5) (2024)
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer 15 (5) (2024)
Mai Suzuki, Ken Uchibori, Tomoko Oh-Hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita, Ryohei Katayama
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer. NPJ precision oncology 8 (1) (2024)
Mai Suzuki, Ken Uchibori, Tomoko Oh-Hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita, Ryohei Katayama
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer. NPJ precision oncology 8 (1) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Yoshiaki Amino, Siew-Kee Low, Hironori Ninomiya, Ayu Kiritani, Keiki Miyadera, Sho Kakuto, Takahiro Akita, Ryosuke Tsugitomi, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Clinical characteristics of patients with KRAS mutation detected by liquid biopsy. Thoracic cancer (2023)
Hiroyuki Sakashita, Ken Uchibori, Yasuto Jin, Toshiharu Tsutsui, Takayuki Honda, Rie Sakakibara, Takahiro Mitsumura, Yoshihisa Nukui, Tsuyoshi Shirai, Masahiro Masuo, Kozo Suhara, Haruhiko Furusawa, Takaaki Yamashita, Takehiko Ohba, Kazuhito Saito, Jun Takagiwa, Yoshihiro Miyashita, Naohiko Inase, Yasunari Miyazaki
A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114). Thoracic cancer 13 (9) (2022)
Yuki Shimizu, Koutaroh Okada, Jun Adachi, Yuichi Abe, Ryohei Narumi, Ken Uchibori, Noriko Yanagitani, Sumie Koike, Satoshi Takagi, Makoto Nishio, Naoya Fujita, Ryohei Katayama
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer. NPJ precision oncology 6 (1) (2022)
Ken Uchibori, Natsuki Takano, Ryo Manabe, Ryosuke Tsugitomi, Shinsuke Ogusu, Takehiro Tozuka, Hiroaki Sakamoto, Hiroshi Yoshida, Yoshiaki Amino, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2. Thoracic cancer 12 (6) (2021)
Ryo Ariyasu, Ken Uchibori, Hironori Ninomiya, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Hiroaki Sakamaoto, Takehiro Tozuka, Hiroshi Yoshida, Yoshiaki Amino, Satoru Kitazono, Noriko Yanagitani, Kengo Takeuchi, Makoto Nishio
Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice. Thoracic cancer 12 (4) (2020)

Ken Uchibori.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ken Uchibori